Insight on Pharmaceuticals and Healthcare in Europe

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Report
Report

The Dyslipidemia Market Outlook to 2021

In the wake of Lipitor’s patent expiry, the dyslipidemia market continues to face increasing genericization leading to falling sales in key drug classes.

Published By Datamonitor
04 Feb 2013 $2800
Buy
Report
Report

The Contract Biomanufacturing Market Outlook to 2017

The biologic drug market is growing at nearly twice the pace of the overall pharma market. This report forecasts microbial and mammalian contract manufacturing markets to 2017. Market dynamics and leading players are also examined.

Published By Datamonitor
19 Feb 2013 $2800
Buy
Case Studies
Case Studies

The "Patent Cliff": How Pfizer has responded to the loss of its best-selling drug

The pharmaceuticals market is currently in the middle of a "patent cliff." This case study looks at the various routes companies are taking in order to minimize the adverse effects caused by the patent cliff.

Published By MarketLine
08 Jun 2012 $495
Buy
Report
Report

Strategies for Comparative Efficacy Trials

Comparative efficacy data are not necessarily required for approval but are increasingly demanded by payers. Meeting the expectations of all stakeholders can be challenging, making comparator selection and trial design complex decisions.

Published By Datamonitor
23 Aug 2012 $2800
Buy
Report
Report

Strategies and Technologies for Target Validation

High Phase II attrition is hampering the pharma industry’s ability to reach sustainable rates of innovation. More rigorous validation of new biological targets prior to clinical development is essential for increasing R&D efficiency.

Published By Datamonitor
28 Sep 2012 $2800
Buy
Report
Report

Stakeholder Opinions: Tropical Diseases - Dengue, Japanese encephalitis and West Nile virus – Increasing attention for neglected diseases

This report explores key issues in dengue, Japanese encephalitis and West Nile infection. It contains an analysis of epidemiological trends, assessment of marketed vaccines and discusses the pipeline for vaccines and virus-specific therapeutics.

Published By Datamonitor
14 Dec 2010 $2800
Buy
Report
Report

Stakeholder Opinions: Sexually Transmitted Diseases - An underestimated threat lacking interventions to prevent transmission

This report covers 4 STDs: chlamydia, gonorrhea, human papillomavirus (HPV), and herpes simplex virus type 2 (HSV-2). It discusses disease background, epidemiology, unmet needs as well as marketed and pipeline therapeutic and preventative strategies.

Published By Datamonitor
05 Aug 2010 $3800
Buy
Report
Report

Stakeholder Opinions: Respiratory viral infections - Respiratory syncytial virus, parainfluenza virus and human metapneumovirus as promising new targets

This report discusses the market opportunity for respiratory antivirals in the seven major markets (7MM). It outlines patient and sales data, provides an analysis of marketed and pipeline drugs, and discusses opportunities and threats in this sector.

Published By Datamonitor
29 Apr 2010 $3800
Buy
Report
Report

Stakeholder Opinions: Ovarian Cancer - Approaching the era of molecular targeted therapy

Key issues in the ovarian cancer market, including forecast epidemiology, current treatment trends and controversies, unmet needs, insight into pipeline activity and stakeholder opinion.

Published By Datamonitor
12 Jul 2010 $3800
Buy
Report
Report

Stakeholder Opinions: Melanoma - Future treatment will be based on individual tumor gene expression signatures

Key issues in the melanoma market including forecast epidemiology data, current treatment patterns and controversies, unmet needs, insight into late-phase pipeline drugs and key stakeholder opinions.

Published By Datamonitor
31 May 2010 $3800
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.